Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals

Anna Søndergaard, Martin Korsbak Madsen, Brice Ozenne, Sophia Armand, Gitte Moos Knudsen, Patrick Mac Donald Fisher, Dea Siggaard Stenbæk*

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

85 Downloads (Pure)

Abstract

Background: Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT2AR) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT2AR binding in the healthy brain. Aim: We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT2AR binding in neocortex and selected frontolimbic regions. Materials and methods: Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [11C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT2AR binding in neocortex and, post-hoc, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex. Results: The MAAS score was significantly increased at 3-month follow-up (p = 3.24 × 10–6), a change positively associated with the MEQ score (p = 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT2AR binding was not significant (p = 0.24), post-hoc analyses revealed a significant negative association between MAAS and right amygdala 5-HT2AR binding (pFWER = 0.008). Conclusion: We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT2AR binding in the right amygdala.

OriginalsprogEngelsk
Artikelnummer948729
TidsskriftFrontiers in Psychology
Vol/bind13
Antal sider11
ISSN1664-1078
DOI
StatusUdgivet - 5. okt. 2022

Bibliografisk note

Funding Information:
Data collected in the present manuscript was supported by the Innovation Fund Denmark (Grant Number 4108-00004B), Independent Research Fund Denmark (Grant Numbers 6110-00518B and 9058-00017B), and The Ester M. og Konrad Kristian Sigurdssons Dyreværns Foundation (Grant Number 850-22-55166-17-LNG). AS was supported through a stipend from The Novo Nordisk Foundation (Grant Number NNF20OC0066082). MM was supported through a stipend from Rigshospitalet’s Research Council (Grant Number R130-A5324). BO was supported by The Lundbeck Foundation (Grant Number R231-2016-3236) and Marie-Curie-NEUROMODEL (Grant Number 746850).

Fingeraftryk

Dyk ned i forskningsemnerne om 'Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals'. Sammen danner de et unikt fingeraftryk.

Citationsformater